NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma
Authors:
Open Access
- 23 August 2024
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-12
Abstract
A high baseline NLR is associated with a poor prognosis of immunotherapy in patients with advanced HCC. As anti-tumour immune activation takes time, early dynamic changes in NLR may serve as a biomarker for predicting immunotherapy response. We conducted a retrospective study in which we enrolled 209 patients with aHCC who received ICIs (training cohort: N = 121, validation cohort: N = 88). In the training cohort, we categorized the patients based on the early changes in their NLR. Specifically, we defined patients as NLR Stable-Responder, NLR Responder and NLR Non-Responder. We compared the outcomes of these three patient groups using survival analysis. Additionally, we shortened the observation period to 6 weeks and validated the findings in the validation cohort. In the training cohort, early dynamic changes in NLR (HR 0.14, 95%CI 0.03–0.65, p = 0.012, HR 0.19, 95%CI 0.07–0.54, p = 0.002; HR 0.21, 95%CI 0.10–0.42, p < 0.001, HR 0.40, 95%CI 0.23–0.69, p = 0.001), PD-L1 < 1% (HR 5.36, 95%CI 1.12–25.66, p = 0.036; HR 2.98, 95%CI 1.51–5.91, p = 0.002) and MVI (HR 3.52, 95%CI 1.28–9.69, p = 0.015; HR 1.99, 95%CI 1.14–3.47, p = 0.015) were identified as independent predictors of OS and PFS. In the validation cohort, when the observation period was reduced to 6 weeks, early NLR changes still have predictive value. Early dynamic changes in NLR may be an easily defined, cost-effective, non-invasive biomarker to predict aHCC response to ICIs.Keywords
This publication has 30 references indexed in Scilit:
- Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitorsNature Communications, 2021
- Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibitionCell, 2021
- Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinomaJournal of Hepatology, 2020
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With SorafenibJAMA Oncology, 2020
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b studyThe Lancet Oncology, 2020
- Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical TrialsJAMA Oncology, 2019
- Improving immune–vascular crosstalk for cancer immunotherapyNature Reviews Immunology, 2018
- Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studiesJournal of Hepatology, 2017
- Predictive biomarkers for checkpoint inhibitor-based immunotherapyThe Lancet Oncology, 2016
- Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinomaHepatology, 2008